SCHEDULE 13D/A: GSK PLC Amends Spero Therapeutics Stake, Ownership Percentage Decreases to 16.4%
Beneficial Ownership Update
GSK PLC has filed an Amendment No. 9 to its Schedule 13D, reporting a decrease in its beneficial ownership of Spero Therapeutics, Inc. common stock to 16.4% due to an increase in Spero's outstanding shares.
Summary
- GSK PLC, a global biopharma company, has filed Amendment No. 9 to its Schedule 13D regarding its investment in Spero Therapeutics, Inc.
- The filing indicates that GSK PLC's beneficial ownership in Spero Therapeutics, Inc. has decreased to 16.4% of the outstanding Common Stock.
- This reduction in percentage ownership is a direct result of an increase in the total outstanding shares of Spero Therapeutics, Inc.
- As of March 21, 2025, Spero Therapeutics, Inc. had 55,900,641 shares of Common Stock outstanding.
- GSK PLC beneficially owns 9,190,606 shares of Spero Therapeutics, Inc. Common Stock.
- The shares are held of record by GSK Equity Investments, Limited and Glaxo Group Limited, both of which are indirect, wholly-owned subsidiaries of GSK plc.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing (Schedule 13D amendment) updating beneficial ownership. It reports a decrease in GSK PLC's percentage ownership in Spero Therapeutics, Inc. due to an increase in Spero's outstanding shares, which is a neutral to slightly negative event for existing shareholders due to dilution, but not indicative of operational performance.
Negatives
- The decrease in GSK PLC's percentage ownership implies dilution for existing shareholders of Spero Therapeutics, Inc. due to an increase in the total outstanding shares.
Risks
- The increase in Spero Therapeutics, Inc.'s outstanding shares, which led to the dilution of GSK PLC's ownership percentage, could indicate a recent capital raise or share issuance by Spero, potentially diluting the value for existing shareholders if not accompanied by commensurate value creation.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding the future operations or financial performance of Spero Therapeutics, Inc. or GSK PLC's investment strategy beyond the current ownership disclosure.
Industry Context
GSK PLC is a global biopharma company focused on uniting science, technology, and talent to address disease. Its investment in Spero Therapeutics, Inc., a Delaware corporation, aligns with its strategic focus on the biopharmaceutical sector. This filing is a routine regulatory update on an existing investment, reflecting changes in the investee company's share structure rather than a new strategic initiative or industry trend.
Stakeholder Impact
- Shareholders (Spero Therapeutics, Inc.): The increase in outstanding shares, which led to the dilution of GSK PLC's ownership percentage, implies a dilution of existing shareholders' ownership stakes.
- Shareholders (GSK PLC): This is a routine compliance filing and does not indicate a direct impact on GSK's share price or operational strategy.
Key Dates
| Date | Description |
|---|---|
| 2017-11-16 | Original Schedule 13D filing date |
| 2018-07-17 | Amendment to Schedule 13D filed |
| 2018-09-19 | Amendment to Schedule 13D filed |
| 2020-02-14 | Amendment to Schedule 13D filed |
| 2020-06-04 | Amendment to Schedule 13D filed |
| 2020-12-07 | Amendment to Schedule 13D filed |
| 2021-09-16 | Amendment to Schedule 13D filed |
| 2022-11-14 | Amendment to Schedule 13D filed |
| 2023-01-20 | Amendment to Schedule 13D filed |
| 2025-03-21 | Date as of which Spero Therapeutics, Inc.'s Common Stock outstanding (55,900,641 shares) was reported in their Form 10-K |
| 2025-03-27 | Date of event which requires filing of this statement (Spero Therapeutics, Inc. Form 10-K furnished to SEC) |
| 2025-03-28 | Signature date of the Schedule 13D Amendment No. 9 |
Keywords
Spero Therapeutics, GSK PLC, Schedule 13D, beneficial ownership, common stock, biopharma, pharmaceutical, SEC filing, ownership percentage, dilution
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.